130 related articles for article (PubMed ID: 38740087)
1. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
Mol Metab; 2024 Jul; 85():101957. PubMed ID: 38740087
[TBL] [Abstract][Full Text] [Related]
2. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
[TBL] [Abstract][Full Text] [Related]
3. The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice.
Rajas F; Dentin R; Cannella Miliano A; Silva M; Raffin M; Levavasseur F; Gautier-Stein A; Postic C; Mithieux G
Mol Metab; 2021 Jan; 43():101108. PubMed ID: 33137488
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
[TBL] [Abstract][Full Text] [Related]
5. Myc and ChREBP transcription factors cooperatively regulate normal and neoplastic hepatocyte proliferation in mice.
Wang H; Dolezal JM; Kulkarni S; Lu J; Mandel J; Jackson LE; Alencastro F; Duncan AW; Prochownik EV
J Biol Chem; 2018 Sep; 293(38):14740-14757. PubMed ID: 30087120
[TBL] [Abstract][Full Text] [Related]
6. Krüppel-like factor 10 protects against metabolic dysfunction-associated steatohepatitis by regulating HNF4α-mediated metabolic pathways.
Pan X; Hu S; Xu Y; Gopoju R; Zhu Y; Cassim Bawa FN; Wang H; Wang J; Batayneh Z; Clark A; Zeng Y; Lin L; Wang X; Yin L; Zhang Y
Metabolism; 2024 Jun; 155():155909. PubMed ID: 38582490
[TBL] [Abstract][Full Text] [Related]
7. The hepatic BMAL1/AKT/lipogenesis axis protects against alcoholic liver disease in mice via promoting PPARα pathway.
Zhang D; Tong X; Nelson BB; Jin E; Sit J; Charney N; Yang M; Omary MB; Yin L
Hepatology; 2018 Sep; 68(3):883-896. PubMed ID: 29534306
[TBL] [Abstract][Full Text] [Related]
8. Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity.
Zhang S; Guo F; Yu M; Yang X; Yao Z; Li Q; Wei Z; Feng K; Zeng P; Zhao D; Li X; Zhu Y; Miao QR; Iwakiri Y; Chen Y; Han J; Duan Y
J Hepatol; 2020 Dec; 73(6):1482-1495. PubMed ID: 32738448
[TBL] [Abstract][Full Text] [Related]
9. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression.
Dentin R; Pégorier JP; Benhamed F; Foufelle F; Ferré P; Fauveau V; Magnuson MA; Girard J; Postic C
J Biol Chem; 2004 May; 279(19):20314-26. PubMed ID: 14985368
[TBL] [Abstract][Full Text] [Related]
10. F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish.
Gong Y; Lu Q; Xi L; Liu Y; Yang B; Su J; Liu H; Jin J; Zhang Z; Yang Y; Zhu X; Xie S; Han D
J Nutr Biochem; 2023 Dec; 122():109452. PubMed ID: 37748621
[TBL] [Abstract][Full Text] [Related]
11. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
12. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.
Fisher FM; Kim M; Doridot L; Cunniff JC; Parker TS; Levine DM; Hellerstein MK; Hudgins LC; Maratos-Flier E; Herman MA
Mol Metab; 2017 Jan; 6(1):14-21. PubMed ID: 28123933
[TBL] [Abstract][Full Text] [Related]
13. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
14. Deletion of hepatic carbohydrate response element binding protein (ChREBP) impairs glucose homeostasis and hepatic insulin sensitivity in mice.
Jois T; Chen W; Howard V; Harvey R; Youngs K; Thalmann C; Saha P; Chan L; Cowley MA; Sleeman MW
Mol Metab; 2017 Nov; 6(11):1381-1394. PubMed ID: 29107286
[TBL] [Abstract][Full Text] [Related]
15. SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1.
Zhu C; Huang M; Kim HG; Chowdhury K; Gao J; Liu S; Wan J; Wei L; Dong XC
Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166249. PubMed ID: 34425214
[TBL] [Abstract][Full Text] [Related]
16. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
[TBL] [Abstract][Full Text] [Related]
17. Treatment with myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-β and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet.
Shimada M; Ichigo Y; Shirouchi B; Takashima S; Inagaki M; Nakagawa T; Hayakawa T
Nutr Res; 2019 Apr; 64():49-55. PubMed ID: 30802722
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver.
Guinez C; Filhoulaud G; Rayah-Benhamed F; Marmier S; Dubuquoy C; Dentin R; Moldes M; Burnol AF; Yang X; Lefebvre T; Girard J; Postic C
Diabetes; 2011 May; 60(5):1399-413. PubMed ID: 21471514
[TBL] [Abstract][Full Text] [Related]
19. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte-specific loss of DDB1 attenuates hepatic steatosis but aggravates liver inflammation and fibrosis in MASH.
Gu Q; Chang Y; Jin Y; Fang J; Ji T; Lin J; Zhu X; Dong B; Ying H; Fan X; Li Z; Gao Z; Zhu Y; Tong Y; Cai X
Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38934719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
